Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-19T02:22:23.890Z Has data issue: false hasContentIssue false
  • English
  • Français

All about PSY DREAM. Psychiatric Drug Registration, Evaluation & All-inclusive Monitoring*

Published online by Cambridge University Press:  11 October 2011

Peter Lehmann
Get access Rights & Permissions [Opens in a new window]

Summary

Aims — In this article the author – board-member of the European Network of (ex-) Users and Survivors of Psychiatry (ENUSP) -explains, what is needed to guarantee a minimal level of involvement of users and survivors of psychiatry into issues relating to psychiatric drugs. Methods – He reflects demands of their organisations, and compares these demands with the current involvement level. Considering the concrete circumstances in psychiatry, he reflects the risks and dangers of the administered drugs -especially the widely used neuroleptics –for example enhanced breast cancer risk in women, suicidal effects, receptor changes, tardive dyskinesia and other toxic reactions. Results – Considering the unique situation of psychiatric patients to receive treatment in general without informed consent and in a violent way or through bullying and threat, he argues for to provide their involvement in all aspects of psychiatric drug issues -especially registration and monitoring, for example by their involvement in creating and running a suicide register. And he argues for involvement in ethics committees, licensing processes and providing guidelines and decision making about effectiveness and reimbursement of costs. Conclusions – As first steps towards these aims he proposes independent and user-controlled research, independent and user-controlled education and independent and user-controlled information about the effects of psychiatric drugs.

Declaration of Interest: the Author did not receive any grants and financial support for the study; any forms of financing (included pharmaceutical company support and any honoraria for consultancies or interventions in the last two years); any other involvements that might be considered a conflict of interest in connection with the submitted article.

Keywords

psychiatric drugsinvolvement of usersregistrationevaluationmonitoring
Type
Inclusion and Mental Health in the New Europe
Information
Epidemiology and Psychiatric Sciences , Volume 14 , Issue 1: Inclusion and Mental Health in the New Europe , March 2005 , pp. 15 - 21
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

(Worked-over) key note lecture at the conference “Inclusion and Mental Health in the New Europe.” run by the European Network for Mental Health Service Evaluation, London. September 3-5, 2004. Translations of the German citations by Peter Lehmann.

References

Ayd, F.J. (1975). The depot fluphenazines. American Journal of Psychiatry 132, 491–500.Google ScholarPubMed
Benkert, O. & Hippius, H. (1980). Psvchiatrische Phannakotherapie, 3. ed. Springer: Berlin/Heidelberg/New York.CrossRefGoogle Scholar
Bradstreet, S. & Norris, R. (Ed.) (2004). All you need to know? Scottish Siurey of People's Experience of Psychiatric Drugs. Scottish Association for Mental Health: Glasgow 2004. Retrieved November 19, 2004, from http://www.samh. org.uk/drugs%20repoit/Full%20reportl. htmGoogle Scholar
Cobb, A., Darton, K. & Juttla, K. (2001). Mind's Yellow Card for Reporting Drug Side Effects. A Report of Users' Experiences. Mind Publications: London.Google Scholar
Degkwitz, R. & Luxenburger, O. (1965). Das terminale extrapyramidale Insuffizienz- bzw. Defektsyndrom infolge chronischer Anwendung von Neurolepticis. Nen-enarzt 36, 173–175.Google Scholar
Ebner, G. (2003). Aktuelles aus der Psychopharmakologie. Das Wichtigste vom ECNP-Kongress. Psychiatrie (Switzerland), online edition. No. 1, 29–32. Retrieved July 13 2004, from http:// www.medpoint.ch/frame.asp?ru=dokument&ArtikelID=10116Google Scholar
ENMESH, European Network for Mental Health Service Evaluation (2004). Conference Programme. ENMESH: London.Google Scholar
ENUSP, European Network of (ex-) Users and Survivors of Psychiatry (1999). Final statement. In The Luxembourg-Report. Documents from the congress “Into the Next Millennium: Moving Forward to Our Own Future,” Luxembourg, February 19-21, 1999. Retrieved September 2, 2004, from http://www.enusp.org/congresses/luxembourg/ final.htmGoogle Scholar
ENUSP, European Network of (ex-)Users and Survivors of Psychiatry (2003a). The European Newsletter of (ex-) Users and Survivors of Psychiatry 11 (special issue). Retrieved September 2, 2004. from http://www.enusp.org/newsletter/2003-6.pdfGoogle Scholar
ENUSP, European Network of (ex-)Users and Survivors of Psychiatry (2003b). The European Newsletter of (ex-) Users and Sunivors of Psychiatry 12 (special issue). Retrieved September 2, 2004, from http://www.enusp.org/newsletter/2003-l 2.pdfGoogle Scholar
Frank, L.R. (1978). The History of Shock Treatment. Self Publication: San Francisco.Google Scholar
Grimond, M. (2004). Drug firms settles Seroxat research claim. The Independent, August 27. Retrieved August 28, 2004, from http://news.independent.co.uk/business/news/story.jsp?story=5555 32Google Scholar
Halbreich, U.. Shen, J. & Panaro, V. (1996). Are chronic psychiatric patients at increased risk for developing breast cancer? American Journal of Psychiatry 153. 559–560.Google ScholarPubMed
Helmchen, H. (1981). Aufkliirung und Einwilligung bei psychisch Kranken. In Psychiatric und Rechtsstaat (ed. Bergener, M. and Andritsch, F.). pp. 79–96. Luchterhand: Darmstadt.Google Scholar
Kempker, K. & Lehmann, P. (ed.) (1993). Statt Psychiatrie. Antipsychiatrieverlag: Berlin.Google Scholar
Lehmann, P. (1981). Was Sie schon immer iiber Psychopharmaka wissen wollten. Die Irren-Offensive-Zeitschrifl von Ver-riickten gegen Psychiatrie 1. 16–21.Google Scholar
Lehmann, P. (1986). Der chemische Knebel-Warum Psychiater Neuroleptika verabreichen. Antipsychiatrieverlag: Berlin.Google Scholar
Lehmann, P. (1996a). Schbne neue Psychiatrie. Vol. I: Wie Chemie und Strom aufGeist und Psyche wirken. Antipsychiatrieverlag: Berlin.Google Scholar
Lehmann, P. (1996b). Schone neue Psychiatrie. Vol. 2: Wie Psychopharmaka den Korper verandern. Antipsychiatrieverlag: Berlin.Google Scholar
Lehmann, P. (Ed.) (1998). Psychopharmaka absetzen. Erfolgreiches Absetzen von Neuroleptika, Antidepressiva, Lithium, Carbamazepin und Tranquilizern. Antipsychiatrieverlag: Berlin.Google Scholar
Lehmann, P. (1999). Forum. The Declaration of Madrid and current psychiatric practice: users' and advocates' views. Current Opinion in Psychiatry 12, 6–7. Retrieved September 2. 2004, from http://www.enusp.org/documents/curr_opinion.htmCrossRefGoogle Scholar
Lehmann, P. (Ed.) (2004). Coming off Psychiatric Drugs. Successful Withdrawal from Neuroleptics, Antidepressants, Lithium, Carbamazepine and Tranquilizers. Peter Lehmann Publishing: Berlin/Eugene/Shrewsbury.Google Scholar
Miiller, P. (1981). Depressive Syndrome im Verlauf schizophrener Psychosen. Enke: Stuttgart. Oaks, D. (1982/83). Thorazine, Mellaril, Haldol, Prolixin: bizarre facts about neuroleptics. Madness Network News 6, 11–13.Google Scholar
Pedler, M. (1999). Forum. The Declaration of Madrid and current psychiatric practice: users' and advocates' views. Current Opinion in Psychiatry 12, 3.CrossRefGoogle Scholar
Peeck, G., von Seckendorff, C. & Heinecke, P. (1995). Ergebnis der Umfrage unter den Mitgliedern des Bundesverbandes Psychiatrieerfahrener zur Qualitat der psychiatrischen Versorgung. Sozialpsychiatrische Informationen 25(4), 30–34. Retrieved September 2, 2004, from http://www.bpe-online.de/infopool /recht/pb/umfrage.htmGoogle Scholar
Reimer, F. (1965). Das “Absetzungs”-Delir. Nervenarzt 34, 446–447.Google Scholar
Sommer, H. & Quandt, J. (1970). Langzeitbehandlung mit Chlorpromazin im Tierexperiment. Fortschritte der Neurologie-Psychiatrie und Hirer Grenzgebiete 38, 466–491.Google Scholar
Tornatore, F.L., Sramek, J.J., Okeya, B.L. & Pi, E.H. (1987). Reactions to Psychotropic Medication. Plenum Pub Corp.: New York/London.Google Scholar
Tornatore, F.L., Sramek, J.J., Okeya, B.L. & Pi, E.H. (1991). Unerwiinschte Wirkungen von Psychopharmaka. Thieme: Stuttgart/New York.Google Scholar
Ungerstedt, U. & Ljungberg, T. (1977). Behavioral patterns related to dopamine neurotransmission. Advances in Biochemical Psychopharmacology 16, 193–199.Google ScholarPubMed
World Health Organization (1997). Quality Assurance in Mental Health Care. Human Rights of People with Mental Disorders. Unpublished draft. WHO: Geneva.Google Scholar
World Health Organization (1999). Conclusions of “Balancing Mental Health Promotion and Mental Health Care: A Joint World Health Organization / European Commission Meeting.” Brussels. 22–24 April 1999. In World Health Organization & European Commission: Balancing Mental Health Promotion and Mental Health Care: A Joint World Health Organization/European Commission Meeting. Brochure MNH/NAM/99.2. Brussels: WHO 1999. 9-10. Retrieved September 2. 2004. from http://wwvv.enusp. orc/documents/consensus.htmGoogle Scholar